North American Thrombosis Forum, AF Action Initiative Consensus Document

American Journal of Medicine

Volumn 129, Issue 5, 2016, Pages S1-S29

  Ruff, Christian T ^a   Ansell, Jack E ^b   Becker, Richard C ^c   Benjamin, Emelia J ^d   Deicicchi, David J ^e   Mark Estes, N A ^f   Ezekowitz, Michael D ^g   Fanikos, John ^h   Fareed, Jawed ⁱ   Garcia, David ^j   Giugliano, Robert P ^a   Goldhaber, Samuel Z ^a   Granger, Christopher ^k   Healey, Jeff S ^l   Hull, Russell ^m   Hylek, Elaine M ^d   Libby, Peter ^a   Lopes, Renato D ^k   Mahaffey, Kenneth W ⁿ   Mega, Jessica ^a   Piazza, Gregory ^a   Sasahara, Arthur A ^a   Sorond, Farzaneh A ^a   Spyropoulos, Alex C ^b   Walenga, Jeanine M ⁱ   Weitz, Jeffrey I ^o   more..

^a HARVARD MEDICAL SCHOOL   (United States)

^b DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^c UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g THOMAS JEFFERSON UNIVERSITY   (United States)

^h NORTHEASTERN UNIVERSITY   (United States)

ⁱ LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^j UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^k DUKE UNIVERSITY MEDICAL CENTER   (United States)

^l MCMASTER UNIVERSITY   (Canada)

^m UNIVERSITY OF CALGARY   (Canada)

ⁿ STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^o MCMASTER UNIVERSITY   (Canada)

more..

Author keywords

Anticoagulants; Antithrombotic management; Atrial fibrillation; Bleeding risk; Stroke

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; BIOLOGICAL MARKER; DABIGATRAN; EDOXABAN; PHENPROCOUMON; RIVAROXABAN; WARFARIN;

ANTICOAGULATION; ATRIAL FIBRILLATION; BLEEDING; BLOOD CLOTTING TEST; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CONSENSUS; HEMODYNAMICS; HUMAN; LABORATORY TEST; NORTH AMERICA; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; THROMBOEMBOLISM; THROMBOSIS; CHEMICALLY INDUCED; CLINICAL DECISION MAKING; COMPLICATION; CONSENSUS DEVELOPMENT; GENETIC PREDISPOSITION; GENETICS; HEALTH STATUS INDICATOR; HEMORRHAGE; MEDICATION COMPLIANCE; METABOLISM; PERIOPERATIVE PERIOD; PRACTICE GUIDELINE; PROCEDURES; PROGNOSIS; RISK FACTOR; STROKE;

ANTICOAGULANTS; ATRIAL FIBRILLATION; BIOMARKERS; CLINICAL DECISION-MAKING; GENETIC PREDISPOSITION TO DISEASE; HEALTH STATUS INDICATORS; HEMORRHAGE; HUMANS; MEDICATION ADHERENCE; PERIOPERATIVE CARE; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; STROKE;

EID: 84965127896     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2016.02.001     Document Type: Article

References (220)

1. V. Fuster, L.E. Ryden, D.S. Cannom, and et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines Circulation 123 2011 e269 e367
2. A.S. Go, E.M. Hylek, K.A. Phillips, and et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study JAMA 285 2001 2370 2375
3. P.A. Wolf, R.D. Abbott, and W.B. Kannel Atrial fibrillation as an independent risk factor for stroke: the Framingham Study Stroke 22 1991 983 988
4. B.F. Gage, A.D. Waterman, W. Shannon, M. Boechler, M.W. Rich, and M.J. Radford Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation JAMA 285 2001 2864 2870
5. G.Y. Lip, R. Nieuwlaat, R. Pisters, D.A. Lane, and H.J. Crijns Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation Chest 137 2010 263 272
6. B.F. Gage, C. van Walraven, L. Pearce, and et al. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin Circulation 110 2004 2287 2292
7. D.E. Singer, G.W. Albers, J.E. Dalen, and et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest 133 2008 546S 592S
8. V. Fuster, L.E. Ryden, D.S. Cannom, and et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society J Am Coll Cardiol 57 2011 e101 e198
9. G. Boriani, G.L. Botto, L. Padeletti, and et al. Improving stroke risk stratification using the CHADS2 and CHA2DS2-VASc risk scores in patients with paroxysmal atrial fibrillation by continuous arrhythmia burden monitoring Stroke 42 2011 1768 1770
10. T.P. Van Staa, E. Setakis, G.L. Di Tanna, D.A. Lane, and G.Y. Lip A comparison of risk stratification schemes for stroke in 79,884 atrial fibrillation patients in general practice J Thromb Haemost 9 2011 39 48
11. G.Y. Lip, L. Frison, J.L. Halperin, and D.A. Lane Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort Stroke 41 2010 2731 2738
12. D. Poli, G.Y. Lip, E. Antonucci, E. Grifoni, and D. Lane Stroke risk stratification in a "real-world" elderly anticoagulated atrial fibrillation population J Cardiovasc Electrophysiol 22 2011 25 30
13. J.B. Olesen, G.Y. Lip, M.L. Hansen, and et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study BMJ 342 2011 d124
14. A.J. Camm, P. Kirchhof, G.Y. Lip, and et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) Eur Heart J 31 2010 2369 2429
15. A.J. Camm, G.Y. Lip, R. De Caterina, and et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association Eur Heart J 33 2012 2719 2747
16. C.T. January, L.S. Wann, J.S. Alpert, and et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society Circulation 130 2014 e199 e267
17. R.J. Beyth, L.M. Quinn, and C.S. Landefeld Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin Am J Med 105 1998 91 99
18. B.F. Gage, Y. Yan, P.E. Milligan, and et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF) Am Heart J 151 2006 713 719
19. T.I. Shireman, J.D. Mahnken, P.A. Howard, T.F. Kresowik, Q. Hou, and E.F. Ellerbeck Development of a contemporary bleeding risk model for elderly warfarin recipients Chest 130 2006 1390 1396
20. G.Y. Lip, L. Frison, J.L. Halperin, and D.A. Lane Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score J Am Coll Cardiol 57 2011 173 180
21. M.C. Fang, A.S. Go, Y. Chang, and et al. A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study J Am Coll Cardiol 58 2011 395 401
22. R.D. Lopes, S.M. Al-Khatib, L. Wallentin, and et al. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial Lancet 380 2012 1749 1758
23. R. Pisters, D.A. Lane, R. Nieuwlaat, C.B. de Vos, H.J. Crijns, and G.Y. Lip A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey Chest 138 2010 1093 1100
24. L. Friberg, J. Engdahl, V. Frykman, E. Svennberg, L.A. Levin, and M. Rosenqvist Population screening of 75- and 76-year-old men and women for silent atrial fibrillation (STROKESTOP) Europace 15 2013 135 140
25. N. Lowres, L. Neubeck, J. Redfern, and S.B. Freedman Screening to identify unknown atrial fibrillation. A systematic review Thromb Haemost 110 2013 213 222
26. H.J. Lin, P.A. Wolf, E.J. Benjamin, A.J. Belanger, and R.B. D'Agostino Newly diagnosed atrial fibrillation and acute stroke. The Framingham Study Stroke 26 1995 1527 1530
27. J.S. Healey, S.J. Connolly, M.R. Gold, and et al. Subclinical atrial fibrillation and the risk of stroke N Engl J Med 366 2012 120 129
28. R. Marfella, F.C. Sasso, M. Siniscalchi, and et al. Brief episodes of silent atrial fibrillation predict clinical vascular brain disease in type 2 diabetic patients J Am Coll Cardiol 62 2013 525 530
29. A. Kishore, A. Vail, A. Majid, and et al. Detection of atrial fibrillation after ischemic stroke or transient ischemic attack: a systematic review and meta-analysis Stroke 45 2014 520 526
30. A.C. Flint, N.M. Banki, X. Ren, V.A. Rao, and A.S. Go Detection of paroxysmal atrial fibrillation by 30-day event monitoring in cryptogenic ischemic stroke: the Stroke and Monitoring for PAF in Real Time (SMART) Registry Stroke 43 2012 2788 2790
31. P.E. Cotter, P.J. Martin, L. Ring, E.A. Warburton, M. Belham, and P.J. Pugh Incidence of atrial fibrillation detected by implantable loop recorders in unexplained stroke Neurology 80 2013 1546 1550
32. A. Culebras, S.R. Messe, S. Chaturvedi, C.S. Kase, and G. Gronseth Summary of evidence-based guideline update: prevention of stroke in nonvalvular atrial fibrillation: report of the Guideline Development Subcommittee of the American Academy of Neurology Neurology 82 2014 716 724
33. R.B. Schnabel, L.M. Sullivan, D. Levy, and et al. Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study Lancet 373 2009 739 745
34. R.B. Schnabel, T. Aspelund, G. Li, and et al. Validation of an atrial fibrillation risk algorithm in whites and African Americans Arch Intern Med 170 2010 1909 1917
35. A.M. Chamberlain, S.K. Agarwal, A.R. Folsom, and et al. A clinical risk score for atrial fibrillation in a biracial prospective cohort (from the Atherosclerosis Risk in Communities [ARIC] study) Am J Cardiol 107 2011 85 91
36. B.M. Everett, N.R. Cook, D. Conen, D.I. Chasman, P.M. Ridker, and C.M. Albert Novel genetic markers improve measures of atrial fibrillation risk prediction Eur Heart J 34 2013 2243 2251
37. A. Alonso, B.P. Krijthe, T. Aspelund, and et al. Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: the CHARGE-AF consortium J Am Heart Assoc 2 2 2013 e000102
38. Z. Hijazi, J. Oldgren, A. Siegbahn, C.B. Granger, and L. Wallentin Biomarkers in atrial fibrillation: a clinical review Eur Heart J 34 2013 1475 1480
39. M.A. Hlatky, P. Greenland, D.K. Arnett, and et al. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association Circulation 119 2009 2408 2416
40. R.B. Schnabel, M.G. Larson, J.F. Yamamoto, and et al. Relations of biomarkers of distinct pathophysiological pathways and atrial fibrillation incidence in the community Circulation 121 2010 200 207
41. J.G. Smith, C. Newton-Cheh, P. Almgren, and et al. Assessment of conventional cardiovascular risk factors and multiple biomarkers for the prediction of incident heart failure and atrial fibrillation J Am Coll Cardiol 56 2010 1712 1719
42. R. Brugada, T. Tapscott, G.Z. Czernuszewicz, and et al. Identification of a genetic locus for familial atrial fibrillation N Engl J Med 336 1997 905 911
43. P.T. Ellinor, D.M. Yoerger, J.N. Ruskin, and C.A. MacRae Familial aggregation in lone atrial fibrillation Hum Genet 118 2005 179 184
44. C.S. Fox, H. Parise, R.B. D'Agostino Sr., and et al. Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring JAMA 291 2004 2851 2855
45. S.A. Lubitz, X. Yin, J.D. Fontes, and et al. Association between familial atrial fibrillation and risk of new-onset atrial fibrillation JAMA 304 2010 2263 2269
46. D.O. Arnar, S. Thorvaldsson, T.A. Manolio, and et al. Familial aggregation of atrial fibrillation in Iceland Eur Heart J 27 2006 708 712
47. D.F. Gudbjartsson, D.O. Arnar, A. Helgadottir, and et al. Variants conferring risk of atrial fibrillation on chromosome 4q25 Nature 448 2007 353 357
48. E.J. Benjamin, K.M. Rice, D.E. Arking, and et al. Variants in ZFHX3 are associated with atrial fibrillation in individuals of European ancestry Nat Genet 41 2009 879 881
49. D.F. Gudbjartsson, H. Holm, S. Gretarsdottir, and et al. A sequence variant in ZFHX3 on 16q22 associates with atrial fibrillation and ischemic stroke Nat Genet 41 2009 876 878
50. P.T. Ellinor, K.L. Lunetta, N.L. Glazer, and et al. Common variants in KCNN3 are associated with lone atrial fibrillation Nat Genet 42 2010 240 244
51. P.T. Ellinor, K.L. Lunetta, C.M. Albert, and et al. Meta-analysis identifies six new susceptibility loci for atrial fibrillation Nat Genet 44 2012 670 675
52. S.A. Lubitz, K.L. Lunetta, H. Lin, and et al. Novel genetic markers associate with atrial fibrillation risk in Europeans and Japanese J Am Coll Cardiol 63 12 2014 1200 1210
53. J.G. Smith, C. Newton-Cheh, P. Almgren, O. Melander, and P.G. Platonov Genetic polymorphisms for estimating risk of atrial fibrillation in the general population: a prospective study Arch Intern Med 172 2012 742 744
54. E.J. Benjamin, P.S. Chen, D.E. Bild, and et al. Prevention of atrial fibrillation: report from a national heart, lung, and blood institute workshop Circulation 119 2009 606 618
55. Z. Hijazi, J. Oldgren, U. Andersson, and et al. Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudy Circulation 125 2012 1605 1616
56. Z. Hijazi, L. Wallentin, A. Siegbahn, and et al. N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation) J Am Coll Cardiol 61 2013 2274 2284
57. Z. Hijazi, A. Siegbahn, U. Andersson, and et al. High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial Circulation 129 2014 625 634
58. Z. Hijazi, L. Wallentin, A. Siegbahn, and et al. High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin J Am Coll Cardiol 63 2014 52 61
59. V. Roldan, F. Marin, J. Diaz, and et al. High sensitivity cardiac troponin T and interleukin-6 predict adverse cardiovascular events and mortality in anticoagulated patients with atrial fibrillation J Thromb Haemost 10 2012 1500 1507
60. A.S. Go, M.C. Fang, N. Udaltsova, and et al. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study Circulation 119 2009 1363 1369
61. S.H. Hohnloser, Z. Hijazi, L. Thomas, and et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial Eur Heart J 33 2012 2821 2830
62. Z. Hijazi, J. Oldgren, U. Andersson, and et al. Cystatin c is prognostic for stroke, death, and bleeding during anticoagulation of atrial fibrillation - a RELY substudy Circulation Abstract suppl 124 2011 A12492
63. J. Eikelboom, Z. Hijazi, J. Oldgren, and et al. D-dimer is prognostic for stroke, major bleeding, and death during anticoagulation of atrial fibrillation - a RELY substudy Circulation Abstract suppl 122 2010 A18321
64. C. Christersson, M. Schollin, J. Alexander, and et al. Increased levels of D-dimer in atrial fibrillation indentify patients with higher risk of thromboembolic events and death Eur Heart J 33 2012 (Abstract Supplement, 51, Abstract session 5297)
65. A. Siegbahn, C. Christersson, M. Schollin, and et al. Increased levels of D-dimer identify patients with atrial fibrillation at high risk for bleeding an ARISTOTLE substudy Eur Heart J 33 2012 (Abstract Supplement 51)
66. G.Y. Lip, J.V. Patel, E. Hughes, and R.G. Hart High-sensitivity C-reactive protein and soluble CD40 ligand as indices of inflammation and platelet activation in 880 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors, stroke risk stratification schema, and prognosis Stroke 38 2007 1229 1237
67. J. Hermida, F.L. Lopez, R. Montes, K. Matsushita, B.C. Astor, and A. Alonso Usefulness of high-sensitivity C-reactive protein to predict mortality in patients with atrial fibrillation (from the Atherosclerosis Risk In Communities [ARIC] Study) Am J Cardiol 109 2012 95 99
68. J.A. Johnson, L. Gong, M. Whirl-Carrillo, and et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing Clin Pharmacol Ther 90 4 2011 625 629
69. S.E. Kimmel, B. French, S.E. Kasner, and et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing N Engl J Med 369 2013 2283 2293
70. J.L. Mega, and R.P. Giugliano Genotype-guided dosing of warfarin Clin Chem 60 2014 920 922
71. M. Pirmohamed, G. Burnside, N. Eriksson, and et al. A randomized trial of genotype-guided dosing of warfarin N Engl J Med 369 2013 2294 2303
72. T.I. Verhoef, G. Ragia, A. de Boer, and et al. A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon N Engl J Med 369 2013 2304 2312
73. J.L. Mega, J.R. Walker, C.T. Ruff, and et al. Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial Lancet 385 9984 2015 2280 2287
74. G. Pare, N. Eriksson, T. Lehr, and et al. Genetic determinants of dabigatran plasma levels and their relation to bleeding Circulation 127 2013 1404 1412
75. R.G. Hart, L.A. Pearce, and M.I. Aguilar Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation Ann Intern Med 146 2007 857 867
76. W. Ageno, A.S. Gallus, A. Wittkowsky, M. Crowther, E.M. Hylek, and G. Palareti Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 141 2012 e44S e88S
77. D. Garcia, S. Regan, M. Crowther, R.A. Hughes, and E.M. Hylek Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population Chest 127 2005 2049 2056
78. A.K. Kakkar, I. Mueller, J.P. Bassand, and et al. Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry PLoS One 8 2013 e63479
79. J.S. Dlott, R.A. George, X. Huang, and et al. National assessment of warfarin anticoagulation therapy for stroke prevention in atrial fibrillation Circulation 129 2014 1407 1414
80. B.I. Eriksson, D.J. Quinlan, and J.I. Weitz Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development Clin Pharmacokinet 48 2009 1 22
81. C. Van der Donckt, J.L. Van Herck, D.M. Schrijvers, and et al. Elastin fragmentation in atherosclerotic mice leads to intraplaque neovascularization, plaque rupture, myocardial infarction, stroke, and sudden death Eur Heart J 36 2015 1049 1058
82. S. Chatterjee, and J. Giri Benefits and risks associated with thrombolysis for pulmonary embolism - reply JAMA 312 2014 1589 1590
83. P. Sardar, R. Nairooz, and S. Chatterjee Intensive glucose control for acute myocardial infarction: an unresolved clinical conundrum JAMA Intern Med 174 2014 825 826
84. J. Ansell Will the new target-specific oral anticoagulants improve the treatment of venous thromboembolism? Thromb Haemost 107 2012 1009 1011
85. C.J. Gonzalez-Quesada, and R.P. Giugliano Comparison of the phase III clinical trial designs of novel oral anticoagulants versus warfarin for the treatment of nonvalvular atrial fibrillation: implications for clinical practice Am J Cardiovasc Drugs 14 2014 111 127
86. N. Matsushima, F. Lee, T. Sato, D. Weiss, and J. Mendell Bioavailability and safety of the factor Xa inhibitor edoxaban and the effects of quinidine in healthy subjects Clin Pharm Drug Dev 2 2013 358 366
87. K. Ogata, J. Mendell-Harary, M. Tachibana, and et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers J Clin Pharmacol 50 2010 743 753
88. C.T. Ruff, and R.P. Giugliano New oral antithrombotic strategies Hot Topics Cardiol 22 2011 7 14
89. S.J. Connolly, M.D. Ezekowitz, S. Yusuf, and et al. Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
90. M.R. Patel, K.W. Mahaffey, J. Garg, and et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 2011 883 891
91. C.B. Granger, J.H. Alexander, J.J. McMurray, and et al. Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 2011 981 992
92. R.P. Giugliano, C.T. Ruff, E. Braunwald, and et al. Edoxaban versus warfarin in patients with atrial fibrillation N Engl J Med 369 2013 2093 2104
93. S. Chatterjee, P. Sardar, G. Biondi-Zoccai, and D.J. Kumbhani Establishing comparable requirements and treatment groups before applying statistical comparison-reply JAMA Neurol 71 2014 371 372
94. S.J. Connolly, M.D. Ezekowitz, S. Yusuf, P.A. Reilly, and L. Wallentin Newly identified events in the RE-LY trial N Engl J Med 363 2010 1875 1876
95. L. Wallentin, S. Yusuf, M.D. Ezekowitz, and et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial Lancet 376 2010 975 983
96. Boehringer Ingelheim. Dabigatran briefing document. Available at: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm226009.pdf. Accessed January 1, 2016.
97. D.J. Graham, M.E. Reichman, M. Wernecke, and et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for non-valvular atrial fibrillation Circulation 131 2014 157 164
98. R. Nagarakanti, M.D. Ezekowitz, J. Oldgren, and et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion Circulation 123 2011 131 136
99. M. Hori, M. Matsumoto, N. Tanahashi, and et al. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation - the J-ROCKET AF study Circ J 76 2012 2104 2111
100. S.J. Connolly, J. Eikelboom, C. Joyner, and et al. Apixaban in patients with atrial fibrillation N Engl J Med 364 2011 806 817
101. D.E. Salazar, J. Mendell, H. Kastrissios, and et al. Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation Thromb Haemost 107 2012 925 936
102. J.J. You, D.E. Singer, P.A. Howard, and et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 141 2012 e531S e575S
103. T. Baglin, A. Hillarp, A. Tripodi, I. Elalamy, H. Buller, and W. Ageno Measuring oral direct inhibitors (ODIs) of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis J Thromb Haemost 11 2013 756 760
104. J. Ansell New oral anticoagulants should not be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation Circulation 125 2012 165 170 discussion 170
105. D. Garcia, Y.C. Barrett, E. Ramacciotti, and J.I. Weitz Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants J Thromb Haemost 11 2013 245 252
106. J. Harenberg, S. Erdle, S. Marx, and R. Kramer Determination of rivaroxaban in human plasma samples Semin Thromb Hemost 38 2012 178 184
107. S. Schulman, and M.A. Crowther How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch Blood 119 2012 3016 3023
108. A. Tripodi The laboratory and the direct oral anticoagulants Blood 121 2013 4032 4035
109. J. van Ryn, J. Stangier, S. Haertter, and et al. Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity Thromb Haemost 103 2010 1116 1127
110. M.M. Samama, G. Contant, T.E. Spiro, and et al. Evaluation of the prothrombin time for measuring rivaroxaban plasma concentrations using calibrators and controls: results of a multicenter field trial Clin Appl Thromb Hemost 18 2012 150 158
111. J. Douxfils, F. Mullier, S. Robert, C. Chatelain, B. Chatelain, and J.M. Dogne Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate Thromb Haemost 107 2012 985 997
112. G. Hapgood, J. Butler, E. Malan, S. Chunilal, and H. Tran The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples Thromb Haemost 110 2013 308 315
113. A. Hillarp, F. Baghaei, I. Fagerberg Blixter, and et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays J Thromb Haemost 9 2011 133 139
114. T.L. Lindahl, F. Baghaei, I.F. Blixter, and et al. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays Thromb Haemost 105 2011 371 378
115. L. Baruch, and O. Sherman Potential inaccuracy of point-of-care INR in dabigatran-treated patients Ann Pharmacother 45 2011 e40
116. E.M. Hawes, A.M. Deal, D. Funk-Adcock, and et al. Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels J Thromb Haemost 11 2013 1493 1502
117. M.M. Samama, G. Contant, T.E. Spiro, and et al. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls Thromb Haemost 107 2012 379 387
118. A. Cuker, D.M. Siegal, M.A. Crowther, and D.A. Garcia Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants J Am Coll Cardiol 64 2014 1128 1139
119. S. Kitchen, E. Gray, I. Mackie, T. Baglin, and M. Makris Measurement of non-coumarin anticoagulants and their effects on tests of Haemostasis: Guidance from the British Committee for Standards in Haematology Br J Haematol 166 2014 830 841
120. C.S. Eby Warfarin replacements: good for patients, challenging for laboratories Clin Chem 59 2013 732 734
121. D. Garcia, M.A. Crowther, and W. Ageno Practical management of coagulopathy associated with warfarin BMJ 340 2010 c1813
122. S. Kaatz, and M. Crowther Reversal of target-specific oral anticoagulants J Thromb Thrombolysis 36 2013 195 202
123. J.I. Weitz, D.J. Quinlan, and J.W. Eikelboom Periprocedural management and approach to bleeding in patients taking dabigatran Circulation 126 2012 2428 2432
124. A. Lazo-Langner, E.S. Lang, and J. Douketis Clinical review: clinical management of new oral anticoagulants: a structured review with emphasis on the reversal of bleeding complications Crit Care 17 2013 230
125. J.I. Weitz, and C.V. Pollack Jr. Practical management of bleeding in patients receiving non-vitamin K antagonist oral anticoagulants Thromb Haemost 114 2015 1113 1126
126. C.V. Pollack Jr., P.A. Reilly, J. Eikelboom, and et al. Idarucizumab for dabigatran reversal N Engl J Med 373 2015 511 520
127. D.M. Siegal, J.T. Curnutte, S.J. Connolly, and et al. Andexanet alfa for the reversal of factor Xa inhibitor activity N Engl J Med 373 2015 2413 2424
128. L.S. Wann, A.B. Curtis, K.A. Ellenbogen, and et al. Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines Circulation 127 2013 1916 1926
129. G. Flaker, R.D. Lopes, S.M. Al-Khatib, and et al. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) J Am Coll Cardiol 63 2014 1082 1087
130. R. Cappato, M.D. Ezekowitz, A.L. Klein, and et al. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation Eur Heart J 35 2014 3346 3355
131. P. Santangeli, L. Di Biase, R. Horton, and et al. Ablation of atrial fibrillation under therapeutic warfarin reduces periprocedural complications: evidence from a meta-analysis Circ Arrhythm Electrophysiol 5 2012 302 311
132. T. Kuwahara, A. Takahashi, Y. Takahashi, and et al. Prevention of periprocedural ischemic stroke and management of hemorrhagic complications in atrial fibrillation ablation under continuous warfarin administration J Cardiovasc Electrophysiol 24 2013 510 515
133. L. Di Biase, J.D. Burkhardt, P. Santangeli, and et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) randomized trial Circulation 129 2014 2638 2644
134. J.I. Weitz, J.S. Healey, A.C. Skanes, and A. Verma Periprocedural management of new oral anticoagulants in patients undergoing atrial fibrillation ablation Circulation 129 2014 1688 1694
135. M. Bassiouny, W. Saliba, J. Rickard, and et al. Use of dabigatran for periprocedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation Circ Arrhythm Electrophysiol 6 2013 460 466
136. D. Lakkireddy, Y.M. Reddy, L. Di Biase, and et al. Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry J Am Coll Cardiol 59 2012 1168 1174
137. R. Providencia, J.P. Albenque, S. Combes, and et al. Safety and efficacy of dabigatran versus warfarin in patients undergoing catheter ablation of atrial fibrillation: a systematic review and meta-analysis Heart 100 2014 324 335
138. D. Lakkireddy, Y.M. Reddy, L. Di Biase, and et al. Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry J Am Coll Cardiol 63 2014 982 988
139. A. Rillig, T. Lin, J. Plesman, and et al. Apixaban, rivaroxaban and dabigatran in patients undergoing atrial fibrillation ablation J Cardiovasc Electrophysiol 27 2 2016 147 153
140. T. Nagao, Y. Inden, S. Yanagisawa, and et al. Differences in activated clotting time among uninterrupted anticoagulants during the periprocedural period of atrial fibrillation ablation Heart Rhythm 12 2015 1972 1978
141. J.D. Douketis, A.C. Spyropoulos, F.A. Spencer, and et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 141 2012 e326S e350S
142. D. Siegal, J. Yudin, S. Kaatz, J.D. Douketis, W. Lim, and A.C. Spyropoulos Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates Circulation 126 2012 1630 1639
143. D.H. Birnie, J.S. Healey, G.A. Wells, and et al. Pacemaker or defibrillator surgery without interruption of anticoagulation N Engl J Med 368 2013 2084 2093
144. J.G. Mathew, A.C. Spyropoulos, A. Yusuf, and et al. Efficacy and safety of early parenteral anticoagulation as a bridge to warfarin after mechanical valve replacement Thromb Haemost 112 2014 1120 1128
145. J.D. Douketis, A.C. Spyropoulos, S. Kaatz, and et al. Perioperative bridging anticoagulation in patients with atrial fibrillation N Engl J Med 373 2015 823 833
146. J.W. Eikelboom, S.J. Connolly, M. Brueckmann, and et al. Dabigatran versus warfarin in patients with mechanical heart valves N Engl J Med 369 2013 1206 1214
147. A.C. Spyropoulos, and J.D. Douketis How I treat anticoagulated patients undergoing an elective procedure or surgery Blood 120 2012 2954 2962
148. M.W. Sherwood, J.D. Douketis, M.R. Patel, and et al. Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF) Circulation 129 2014 1850 1859
149. D. Garcia, J.H. Alexander, L. Wallentin, and et al. Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures Blood 124 2014 3692 3698
150. J.S. Healey, J. Eikelboom, J. Douketis, and et al. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial Circulation 126 2012 343 348
151. J.D. Douketis, J.S. Healey, M. Brueckmann, and et al. Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients with an elective surgery or procedure. Substudy of the RE-LY trial Thromb Haemost 113 2015 625 632
152. Kovacs M. PERIOP2 - A safety and effectiveness study of LMWH bridging therapy versus placebo bridging therapy for patients on long term warfarin and require temporary interruption of their warfarin. ClinicalTrials.gov Identifier: NCT00432796. Available at: https://www.clinicaltrials.gov/ct2/show/NCT00432796. Accessed July 28, 2015.
153. Ortel T, Hasselblad V. Effectiveness of bridging anticoagulation for surgery (the BRIDGE study). ClinicalTrials.gov Identifier: NCT00786474. Available at: https://clinicaltrials.gov/ct2/results?term=Ortel+T%2C+Hasselblad+V.+Effectiveness+of+bridging+anticoagulation+for+surgery+%28the+BRIDGE+study%29.+ClinicalTrials.gov+Identifier%3A+Q21+NCT00786474.+Available+at%3A+ -.+Accessed+April+29%2C+2015.&Search=Search. Accessed April 29, 2015.
154. Douketis J, Duncan J. Perioperative anticoagulant use for surgery evaluation study (PAUSE). ClinicalTrials.gov Identifier: NCT02228798. Available at: https://clinicaltrials.gov/ct2/show/NCT00786474. Accessed April 29, 2015.
155. E.M. Hylek, L. Frison, L.E. Henault, and A. Cupples Disparate stroke rates on warfarin among contemporaneous cohorts with atrial fibrillation: potential insights into risk from a comparative analysis of SPORTIF III versus SPORTIF V Stroke 39 2008 3009 3014
156. C.T. Ruff, R.P. Giugliano, E. Braunwald, and et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials Lancet 383 2014 955 962
157. M.D. Ezekowitz, L. Wallentin, S.J. Connolly, and et al. Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation Circulation 122 2010 2246 2253
158. D.A. Garcia, L. Wallentin, R.D. Lopes, and et al. Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial Am Heart J 166 2013 549 558
159. K.W. Mahaffey, S.R. Stevens, H.D. White, and et al. Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial Eur Heart J 35 2014 233 241
160. C. van Walraven, R.G. Hart, S. Connolly, and et al. Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators Stroke 40 2009 1410 1416
161. F.J. van der Meer, F.R. Rosendaal, J.P. Vandenbroucke, and E. Briet Bleeding complications in oral anticoagulant therapy. An analysis of risk factors Arch Intern Med 153 1993 1557 1562
162. J.W. Eikelboom, L. Wallentin, S.J. Connolly, and et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial Circulation 123 2011 2363 2372
163. M. Coppens, J. Eikelboom, M. Ezekowitz, and et al. Abstract 15537: dabigatran versus warfarin in very elderly patients with atrial fibrillation: results from the RE-LY trial Circulation 126 2012 A15537
164. J.L. Halperin, D. Wojdyla, J.P. Piccini, and et al. Abstract 148: efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the ROCKET-AF trial Stroke 43 2012 A148
165. L.E. Dobson, R.J. Lewin, P. Doherty, P.D. Batin, S. Megarry, and C.P. Gale Is cardiac rehabilitation still relevant in the new millennium? J Cardiovasc Med (Hagerstown) 13 2012 32 37
166. E.T. Kato, R.P. Giugliano, C.T. Ruff, and et al. Abstract 16612: efficacy and safety of edoxaban for the management of elderly patients with atrial fibrillation: engage AF-TIMI 48 Circulation 130 2014 A16612
167. S.D. Pokorney, M.W. Sherwood, and R.C. Becker Clinical strategies for selecting oral anticoagulants in patients with atrial fibrillation J Thromb Thrombolysis 36 2013 163 174
168. Z. Hijazi, S.H. Hohnloser, J. Oldgren, and et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis Circulation 129 2014 961 970
169. S.H. Hohnloser, J. Oldgren, S. Yang, and et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial Circulation 125 2012 669 676
170. K.A. Fox, J.P. Piccini, D. Wojdyla, and et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment Eur Heart J 32 2011 2387 2394
171. C.T. Ruff, R.P. Giugliano, E. Braunwald, and et al. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial Lancet 385 2015 2288 2295
172. D. Vivas, C. Olmos, and I. Vilacosta Atrial fibrillation and anticoagulation therapy: different race, different risk, and different management? Circ J 75 2011 1314 1315
173. W. Hernandez, K. Aquino-Michaels, K. Drozda, and et al. Novel single nucleotide polymorphism in CYP2C9 is associated with changes in warfarin clearance and CYP2C9 expression levels in African Americans Transl Res 165 6 2015 651 657
174. E.M. Hylek, D. Ko, and C.L. Cove Gaps in translation from trials to practice: non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in atrial fibrillation Thromb Haemost 111 2014 783 788
175. E.M. Antman, M. Cohen, P.J. Bernink, and et al. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making JAMA 284 2000 835 842
176. K.A. Fox, O.H. Dabbous, R.J. Goldberg, and et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE) BMJ 333 2006 1091
177. H. Jneid, J.L. Anderson, R.S. Wright, and et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 60 2012 645 681
178. P.T. O'Gara, F.G. Kushner, D.D. Ascheim, and et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 61 2013 e78 e140
179. J.W. Wisler, and R.C. Becker A guidance pathway for the selection of novel anticoagulants in the treatment of atrial fibrillation Crit Pathw Cardiol 11 2012 55 61
180. S. Sjalander, A. Sjalander, P.J. Svensson, and L. Friberg Atrial fibrillation patients do not benefit from acetylsalicylic acid Europace 16 2014 631 638
181. F. Dentali, N. Riva, M. Crowther, A.G. Turpie, G.Y. Lip, and W. Ageno Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature Circulation 126 2012 2381 2391
182. A.L. Dans, S.J. Connolly, L. Wallentin, and et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial Circulation 127 2013 634 640
183. W.J. Dewilde, T. Oirbans, F.W. Verheugt, and et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial Lancet 381 2013 1107 1115
184. J.H. Alexander, R.D. Lopes, S. James, and et al. Apixaban with antiplatelet therapy after acute coronary syndrome N Engl J Med 365 2011 699 708
185. J.L. Mega, E. Braunwald, S.D. Wiviott, and et al. Rivaroxaban in patients with a recent acute coronary syndrome N Engl J Med 366 2012 9 19
186. L. Mauri, D.J. Kereiakes, R.W. Yeh, and et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents N Engl J Med 371 2014 2155 2166
187. V.Y. Reddy, S.K. Doshi, H. Sievert, and et al. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-year follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial Circulation 127 6 2013 720 729
188. V.Y. Reddy, S. Mobius-Winkler, M.A. Miller, and et al. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology) J Am Coll Cardiol 61 2013 2551 2556
189. J.W. Park, A. Bethencourt, H. Sievert, and et al. Left atrial appendage closure with Amplatzer cardiac plug in atrial fibrillation: initial European experience Catheter Cardiovasc Interv 77 5 2011 700 706
190. K. Bartus, F.T. Han, J. Bednarek, and et al. Percutaneous left atrial appendage suture ligation using the LARIAT device in patients with atrial fibrillation: initial clinical experience J Am Coll Cardiol 62 2013 108 118
191. T.V. Glotzer, E.G. Daoud, D.G. Wyse, and et al. The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study Circ Arrhythm Electrophysiol 2 2009 474 480
192. G.Y. Lip, A.J. Camm, E.M. Hylek, J.L. Halperin, and J.I. Weitz Non-vitamin K antagonist oral anticoagulants: an appeal for consensus on terminology Chest 145 2014 1177 1178
193. E.G. Daoud, T.V. Glotzer, D.G. Wyse, and et al. Temporal relationship of atrial tachyarrhythmias, cerebrovascular events, and systemic emboli based on stored device data: a subgroup analysis of TRENDS Heart Rhythm 8 2011 1416 1423
194. M. Brambatti, S.J. Connolly, M.R. Gold, and et al. Temporal relationship between subclinical atrial fibrillation and embolic events Circulation 129 2014 2094 2099
195. K. Anderson, and B. Benzauqen Do patients with pacemaker-detected atrial fibrillation receive appropriate anticoagulation? Europace 13 2011 P519
196. J.S. Healey, J.L. Martin, A. Duncan, and et al. Pacemaker-detected atrial fibrillation in patients with pacemakers: prevalence, predictors, and current use of oral anticoagulation Can J Cardiol 29 2013 224 228
197. J. Ip, A.L. Waldo, G.Y. Lip, and et al. Multicenter randomized study of anticoagulation guided by remote rhythm monitoring in patients with implantable cardioverter-defibrillator and CRT-D devices: rationale, design, and clinical characteristics of the initially enrolled cohort The IMPACT study Am Heart J 158 2009 364 370
198. J. Ansell, J. Hirsh, E. Hylek, A. Jacobson, M. Crowther, and G. Palareti Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest 133 2008 160S 198S
199. S.R. Ghate, J. Biskupiak, X. Ye, W.J. Kwong, and D.I. Brixner All-cause and bleeding-related health care costs in warfarin-treated patients with atrial fibrillation J Manag Care Pharm 17 2011 672 684
200. J.V. Freeman, R.P. Zhu, D.K. Owens, and et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation Ann Intern Med 154 2011 1 11
201. S.V. Shah, and B.F. Gage Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation Circulation 123 2011 2562 2570
202. A. Amin, M. Stokes, N. Wu, and et al. Estimated medical cost reductions associated with apixaban in real-world patients with non-valvular atrial fibrillation J Med Econ 16 2013 1193 1202
203. J.M. Hwang, J. Clemente, K.P. Sharma, T.N. Taylor, and C.L. Garwood Transportation cost of anticoagulation clinic visits in an urban setting J Manag Care Pharm 17 2011 635 640
204. D.E. Jonas, B. Bryant Shilliday, W.R. Laundon, and M. Pignone Patient time requirements for anticoagulation therapy with warfarin Med Decis Making 30 2010 206 216
205. Centers for Disease Control and Prevention (CDC) US Prescription Drug Data 2014 Available at: http://www.cdc.gov/nchs/data/databriefs/db42.htm Accessed May 12, 2014
206. Centers for Disease Control and Prevention (CDC). Health, United States, 2010: with special feature on death and dying. Available at: http://www.cdc.gov/nchs/data/hus/hus10.pdf. Accessed May 12, 2014.
207. Office of Inspector General US Department of Health and Human Services Medication Regimens: Cause of Non Compliance 2014 Available at: http://oig.hhs.gov/oei/reports/oei-04-89-89121.pdf Accessed May 12, 2014
208. L. Osterberg, and T. Blaschke Adherence to medication N Engl J Med 353 2005 487 497
209. M.C. Sokol, K.A. McGuigan, R.R. Verbrugge, and R.S. Epstein Impact of medication adherence on hospitalization risk and healthcare cost Med Care 43 2005 521 530
210. F. Van de Werf, M. Brueckmann, S.J. Connolly, and et al. A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: THE Randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN) Am Heart J 163 2012 931 937
211. A.J. Forster, H.J. Murff, J.F. Peterson, T.K. Gandhi, and D.W. Bates The incidence and severity of adverse events affecting patients after discharge from the hospital Ann Intern Med 138 2003 161 167
212. D.S. Budnitz, N. Shehab, S.R. Kegler, and C.L. Richards Medication use leading to emergency department visits for adverse drug events in older adults Ann Intern Med 147 2007 755 765
213. G. Pernod, J. Labarere, J. Yver, and et al. EDUC'AVK: reduction of oral anticoagulant-related adverse events after patient education: a prospective multicenter open randomized study J Gen Intern Med 23 9 2008 1441 1446
214. S.M. Wilhelm, and E.A. Petrovitch Implementation of an inpatient anticoagulation teaching service: expanding the role of pharmacy students and residents in patient education Am J Health Syst Pharm 68 2011 2086 2093
215. Joint Commission. Anticoagulation therapy, NPSG 03.05.01. Available at: www.jointcommission.org/assets/1/6/2011-NPSGs-HAP.pdf. Accessed June 27, 2011.
216. D.B. Matchar, A. Jacobson, R. Dolor, and et al. Effect of home testing of international normalized ratio on clinical events N Engl J Med 363 2010 1608 1620
217. H. Kortke, and R. Korfer International normalized ratio self-management after mechanical heart valve replacement: is an early start advantageous? Ann Thorac Surg 72 2001 44 48
218. H. Voller, J. Glatz, U. Taborski, A. Bernardo, C. Dovifat, and K. Heidinger Self-management of oral anticoagulation in nonvalvular atrial fibrillation (SMAAF study) Z Kardiol 94 2005 182 186
219. H.H. Watzke, E. Forberg, G. Svolba, E. Jimenez-Boj, and B. Krinninger A prospective controlled trial comparing weekly self-testing and self-dosing with the standard management of patients on stable oral anticoagulation Thromb Haemost 83 2000 661 665
220. T.I. Khan, F. Kamali, P. Kesteven, P. Avery, and H. Wynne The value of education and self-monitoring in the management of warfarin therapy in older patients with unstable control of anticoagulation Br J Haematol 126 2004 557 564